ICD-10-CM Billable Code

C81.29

Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites

Clinical Classification Guidelines

Medical Intelligence & Overview

Mixed cellularity Hodgkin lymphoma (ICHL) is a subtype of Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. This form is characterized by a diverse mix of cells within the affected lymph nodes or other organs. When it involves both lymphatic and extranodal (beyond lymph nodes) solid organ sites, it is classified under the ICD-10 code C81.29. Recognizing the features of this disease can help in understanding its progression, diagnosis, and treatment options. Though a serious condition, advancements in medical research have improved patient outcomes through targeted therapies and comprehensive care.

Causes & Symptoms

Clinical Causes: Genetic factors that may predispose individuals to lymphoid cancers. Previous exposure to radiation or certain chemicals such as pesticides and solvents. Weakened immune system due to infections (like Epstein-Barr virus) or immunosuppressive therapies. Family history of Hodgkin lymphoma or other lymphoid cancers. Age-related factors, with higher incidence often seen in young adults and those over 55.

Key Symptoms: Swollen lymph nodes commonly in the neck, armpits, or groin that are painless. Unexplained persistent fever. Night sweats that drench clothing. Unexplained weight loss. Fatigue and general weakness. Itching of the skin without an apparent cause. Pain or discomfort when drinking alcohol, especially in affected lymph nodes. Symptoms related to extranodal organ involvement, which can include abdominal pain, cough, or neurological symptoms depending on the organs affected.

Diagnostic & Treatment

Diagnosis Path: Physical examination: Checking for swollen lymph nodes or swelling in other areas. Imaging studies: PET scans, CT scans, or MRI to identify the extent of disease involvement. Biopsy: Removing a tissue sample from a swollen lymph node or affected organ for microscopic examination to identify Reed-Sternberg cells and other cellular components characteristic of Hodgkin lymphoma. Blood tests: To assess overall health and organ function, and to identify any abnormalities. Bone marrow biopsy: To check whether the disease has spread to the marrow.

Treatment Protocols: Chemotherapy: Using drugs to kill cancer cells, typically employing regimes like ABVD or escalated BEACOPP. Radiation therapy: Targeted radiation to affected lymph nodes or organs, often used after chemotherapy to eradicate residual disease. Immunotherapy: Agents that help the immune system recognize and attack cancer cells, such as checkpoint inhibitors. Targeted therapy: Drugs designed to interfere with specific molecules involved in the growth of cancer cells. Stem cell transplant: Usually considered in relapsed or refractory cases, involving the transplantation of healthy stem cells to restore bone marrow function.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C81.29 a billable ICD-10 code?
Yes, C81.29 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C81.29?
Clinical documentation must specify the nature of Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites and any associated comorbidities for accurate reporting.

Cite this Clinical Reference